| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1829 | 2009 |
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005 | 1822 | 2005 |
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy MK Higashi, DL Veenstra, LM Kondo, AK Wittkowsky, ... Jama 287 (13), 1690-1698, 2002 | 1400 | 2002 |
| The human intestinal cytochrome P450 “pie” MF Paine, HL Hart, SS Ludington, RL Haining, AE Rettie, DC Zeldin Drug metabolism and disposition 34 (5), 880-886, 2006 | 1037 | 2006 |
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 988 | 2008 |
| Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions AE Rettie, KR Korzekwa, KL Kunze, RF Lawrence, AC Eddy, T Aoyama, ... Chemical research in toxicology 5 (1), 54-59, 1992 | 776 | 1992 |
| Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites KR Korzekwa, N Krishnamachary, M Shou, A Ogai, RA Parise, AE Rettie, ... Biochemistry 37 (12), 4137-4147, 1998 | 648 | 1998 |
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 AE Rettie, LC Wienkers, FJ Gonzalez, WF Trager, KR Korzekwa Pharmacogenetics and Genomics 4 (1), 39-42, 1994 | 630 | 1994 |
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ... Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008 | 530 | 2008 |
| CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant MG McDonald, MJ Rieder, M Nakano, CK Hsia, AE Rettie Molecular pharmacology 75 (6), 1337-1346, 2009 | 434 | 2009 |
| Genetic association between sensitivity to warfarin and expression of CYP2C9* 3 DJ Steward, RL Haining, KR Henne, G Davis, TH Rushmore, WF Trager, ... Pharmacogenetics and Genomics 7 (5), 361-367, 1997 | 381 | 1997 |
| Identification and functional characterization of a new CYP2C9 variant (CYP2C9* 5) expressed among African Americans LJ Dickmann, AE Rettie, MB Kneller, RB Kim, AJJ Wood, CM Stein, ... Molecular pharmacology 60 (2), 382-387, 2001 | 362 | 2001 |
| Developmental expression of human hepatic CYP2C9 and CYP2C19 SB Koukouritaki, JR Manro, SA Marsh, JC Stevens, AE Rettie, ... Journal of Pharmacology and Experimental Therapeutics 308 (3), 965-974, 2004 | 357 | 2004 |
| Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics AE Rettie, JP Jones Annu. Rev. Pharmacol. Toxicol. 45, 477-494, 2005 | 346 | 2005 |
| Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3 DH Lang, CK Yeung, RM Peter, C Ibarra, R Gasser, K Itagaki, RM Philpot, ... Biochemical pharmacology 56 (8), 1005-1012, 1998 | 343 | 1998 |
| Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral … RL Haining, AP Hunter, ME Veronese, WF Trager, AE Rettie Archives of biochemistry and biophysics 333 (2), 447-458, 1996 | 337 | 1996 |
| Cytochrome P-450—Catalyzed Formation of Δ4-VPA, a Toxic Metabolite of Valproic Acid AE Rettie, AW Rettenmeier, WN Howald, TA Baillie Science 235 (4791), 890-893, 1987 | 330 | 1987 |
| Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression SB Koukouritaki, P Simpson, CK Yeung, AE Rettie, RN Hines Pediatric research 51 (2), 236-243, 2002 | 298 | 2002 |
| Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6 W Chen, LL Koenigs, SJ Thompson, RM Peter, AE Rettie, WF Trager, ... Chemical research in toxicology 11 (4), 295-301, 1998 | 291 | 1998 |
| Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population DL Veenstra, JHS You, MJ Rieder, FM Farin, HW Wilkerson, DK Blough, ... Pharmacogenetics and genomics 15 (10), 687-691, 2005 | 288 | 2005 |
